Segment Information (Notes)

6 Months Ended

Jun. 30, 2017

Segment Reporting Information [Line Items]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

18. Segment Information

In connection with acquiring 100% of the equity interests of LENSAR in May 2017, the Company added a third reportable segment, “medical devices” and renamed the previous product sales segment “pharmaceutical”.

Information regarding the Company’s segments for the three and six months endedJune 30, 2017 and 2016 is as follows:

Revenues by segment	Three Months Ended				Six Months Ended
	June 30,				June 30,
(in thousands)	2017		2016		2017		2016
Income generating assets	$	125,006	$	21,047	$	157,864	$	124,171
Pharmaceutical	16,212		—		28,794		—
Medical devices	2,617		—		2,617		—
Total revenues	$	143,835	$	21,047	$	189,275	$	124,171

Income (loss) by segment	Three Months Ended					Six Months Ended
	June 30,					June 30,
(in thousands)	2017			2016		2017			2016
Income generating assets	$	62,525		$	4,148	$	73,499		$	60,035
Pharmaceutical	(891		)	—		(4,624		)	—
Medical devices	(1,195		)	—		(1,195		)	—
Total net income	$	60,439		$	4,148	$	67,680		$	60,035

Long-lived assets by segment
(in thousands)	June 30, 2017		December 31, 2016
Income generating assets	$	61	$	38
Pharmaceutical	844		—
Medical devices	1,295		—
Total long-lived assets	$	2,200	$	38

The operations for the Company’s Pharmaceutical and Medical Devices segments are primarily located in Ireland and the United Stated, respectively.